Triferic Pediatric Pharmacokinetic Protocol

• Status: Completed
• Trial end date: 2017-01-01

Summary

The main purpose is to determine the pharmacokinetics (PK) of Triferic iron administered intravenously in pediatric patients with chronic kidney disease on chronic hemodialysis (CKD-5HD). It is an open-label, two-period sequential dosing study.

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: Rockwell Medical Technologies, Inc.
• Treatments: Citric Acid; Hemodialysis Solutions; Iron